文献速递核素与放射性配体治疗肿瘤 PET/CT

累积吸收剂量与逐周期吸收剂量下降可预测177Lu-DOTATATE治疗神经内分泌肿瘤的疗效

Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2026-05-01

该研究基于OZM-067多中心试验中73例接受4周期[177Lu]Lu-DOTATATE治疗的神经内分泌肿瘤患者,利用SPECT/CT图像衍生剂量学指标预测RECIST 1.1评估的影像学反应。结果显示,缓解者的累积吸收剂量(AD)更高且逐周期AD/AA下降幅度更大,两者为不相关的预测因子(P=0.64),联合模型的AUC为0.78。

要点

  • 缓解者累积AD更高且逐周期AD/AA下降更明显
  • AD与AD/AA变化是不相关的独立预测因子(P=0.64)
  • 联合AD与AD/AA变化的模型AUC为0.78

核心结论

  • 累积吸收剂量与逐周期AD/AA变化均独立与[177Lu]Lu-DOTATATE的影像学反应相关。
  • 治疗过程中AD/AA持续下降,提示其可作为指导适应性治疗策略的潜在影像生物标志物。

研究设计与样本

  • 分析OZM-067多中心试验(NCT02743741)中73例接受4周期[177Lu]Lu-DOTATATE治疗且每周期后3个时间点行SPECT/CT的患者。
  • 肿瘤剂量学基于半自动自适应阈值分割与恢复系数部分容积校正,排除小于10 cm³的肿瘤。
  • 若患者有多个肿瘤被分割,每周期记录平均吸收剂量(AD)与AD/AA;影像学反应采用RECIST 1.1评估。

主要发现

  • AD/AA逐周期显著下降,中位每周期降幅约10%。
  • 队列中28例部分缓解、33例疾病稳定、12例疾病进展。
  • 与未缓解者相比,缓解者的平均累积AD更高且逐周期AD/AA下降幅度更大。
  • AD与AD/AA变化为不相关预测因子(P=0.64)。
  • AD≥100 Gy且第1至第4周期AD/AA下降≥50%的8例患者均为缓解者。

关键数值与推荐

  • 影像学反应采用RECIST 1.1标准评估。
  • AD与AD/AA变化联合模型的受试者工作特征曲线下面积为0.78。

临床怎么用

  • 图像衍生剂量学指标(累积AD及逐周期AD/AA变化)可用于预测[177Lu]Lu-DOTATATE的影像学反应。
  • AD/AA持续下降提示可考虑用于适应性治疗策略,但需在前瞻性研究中进一步评估。

局限性

  • 研究为对OZM-067试验数据的分析,结论需在前瞻性设置中进一步验证。
  • 剂量学分析排除小于10 cm³的肿瘤,可能限制结论对小病灶的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to use image-derived dose metrics to predict the radiologic response of neuroendocrine tumors treated with [177Lu]Lu-DOTATATE. Particular focus was given to the evaluation of cyclic changes in absorbed dose per administered activity (AD/AA) as a potential prognostic factor. Methods: Data from 73 patients enrolled in the multicenter OZM-067 trial (NCT02743741) were analyzed. All patients who received 4 cycles of [177Lu]Lu-DOTATATE and underwent SPECT/CT imaging at 3 time points after each treatment were included. Tumor dosimetry was based on semiautomatic adaptive-threshold segmentations and recovery coefficient-based partial-volume correction; tumors smaller than 10 cm³ were excluded. If multiple tumors were segmented per patient, the mean absorbed dose (AD) and AD/AA were recorded at each cycle. Radiologic response was assessed using RECIST 1.1 criteria. Results: A significant decrease in AD/AA across cycles was observed, with a median decline of approximately 10% per cycle. Within this cohort, 28 patients had a partial response, 33 had stable disease, and 12 experienced disease progression. Responders exhibited a higher mean cumulative AD and greater decreases in AD/AA in successive cycles when compared with nonresponders. These metrics were uncorrelated predictors of response (P = 0.64). Notably, all 8 patients with an AD of at least 100 Gy and a decrease of at least 50% in AD/AA between cycles 1 and 4 were responders. Quantitative models combining AD and changes in AD/AA achieved an area under the receiver-operating-characteristic curve of 0.78. Conclusion: Both AD and changes in AD/AA were independently associated with radiologic response to [177Lu]Lu-DOTATATE in patients with neuroendocrine tumors. The consistent decrease in AD/AA over a course of therapy suggests a potential imaging biomarker that could inform adaptive treatment strategies, which should be further evaluated in a prospective setting and considered when designing dosimetry-guided [177Lu]Lu-DOTATATE trials.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Macsuka MJ, Driscoll B, Yeung IWT, et al. Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med. 2026. PMID: 41611479. doi:10.2967/jnumed.125.271039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。